|
Report Title |
Publish
Date |
Price |
Order |
 |
Cardiovascular and metabolic market overview forecast model
|
Jan-10 |
$15,200 |
 |
|
 |
Commercial Insight: Cardiovascular and metabolic market overview - Innovative development pipeline provides limited growth as primary care markets become generic
|
Jan-10 |
$15,200 |
|
|
 |
Commercial Insight: Molecular Targeted Cancer Therapies - Leading companies will hold onto competitive advantage in high growth market
|
Aug-09 |
$15,200 |
|
|
 |
Commercial Insight: Influenza Vaccines and Antivirals
|
Aug-09 |
$15,200 |
|
|
 |
Commercial Insight: Cytotoxic Therapies - Market growth will slow due to increasing genericization
|
Jun-09 |
$15,200 |
|
|
 |
Forecast Insight: HIV - Cross-class fixed dose combinations drive continued growth
|
Jun-09 |
$15,200 |
|
|
 |
Biosimilars Series: Forecast Analysis
|
Jun-09 |
$11,400 |
|
|
 |
Emerging Markets Series: The Pharmaceutical Market of Poland
|
Jun-09 |
$5,700 |
|
|
 |
Forecast Insight: Fibromyalgia - Regulatory caution threatens EU market expansion
|
Jun-09 |
$15,200 |
|
|
 |
Emerging Markets Series: The Pharmaceutical Market of Saudi Arabia
|
Jun-09 |
$5,700 |
|
|
 |
Generic Benchmarking: Brand Erosion at Patent Expiry
|
Mar-09 |
$7,600 |
|
|
 |
Healthcare: Global Industry Guide
|
Apr-09 |
$555 |
|
|
 |
Stakeholder Insight: Psoriasis - Biologics are yet to make topical treatments obsolete
|
Mar-09 |
$15,200 |
|
|
 |
Stakeholder Opinions: Cancer Cachexia - Higher profile needed to unlock market potential of neglected syndrome
|
Jan-09 |
$3,800 |
|
|
 |
Stakeholder Opinions: Cystic Fibrosis - A pipeline full of hope
|
Mar-09 |
$3,800 |
|
|
 |
Commercial Insight: Cardiovascular and metabolic market overview Diabetes to the fore as generics hit primary care markets
|
Feb-09 |
$15,200 |
|
|
 |
Stakeholder Opinions: Pancreatic Cancer - Gemzar dominance will continue among high levels of persistent unmet needs
|
Mar-09 |
$3,800 |
|
|
 |
Stakeholder Opinions: Physician perception of biologics in autoimmune disease - Targeted detailing is the key to success
|
Mar-09 |
$3,800
Save 15% now through May 31 |
|
|
 |
Pricing
and Reimbursement in Key Asia Pacific Markets
|
Jan-09 |
$3,800 |
|
|
 |
Forecast
Insight: Antithrombotics - Market growth dependent on new agents
|
Dec-08 |
$15,200 |
|
|
 |
Pharmaceutical Company Outlook to 2013
|
Dec-08 |
Save 10%
$7,600 |
|
|
 |
Commercial Insight: Community Antibacterials - Pipelines wither
as generic tidal wave takes its toll
|
Jan-09 |
$15,200 |
|
|
 |
Commercial Insight: Rheumatoid arthritis - Anti-TNFs defend
first-line biologic position despite competition
|
Dec-08 |
$15,200 |
|
|
 |
Pipeline
Insight: Cancer Overview - Gastrointestinal, Skin, Sarcomas
|
Dec-08 |
$11,400 |
|
|
 |
Infectious Diseases Vaccine Market Overview: Key Companies &
Strategies - In times of crisis, Big Pharma turns to vaccines
|
Dec-08 |
$15,200 |
|
|
|
|
Pipeline and
Commercial Insight: Hepatitis C - High unmet need drives rapid
innovation
|
Dec-08 |
$15,200 |
|
|
 |
Biotechnology: Global Industry Guide
|
Nov-08 |
$1,495 |
|
|
 |
Financial Deals Industry Tracker: Pharmaceuticals and Healthcare September 2008 (analysis of merger and acquisition (M&A), private equity, venture financing, private placement, initial public offering (IPO), and secondary offering deals)
|
Nov-08 |
$495 |
|
|
 |
Stakeholder Opinions: Diabetic Renal Disease
|
Nov-08 |
$3,800 |
|
|
 |
Pipeline Insight: Orphan Diseases in Neurology - Part III: Myasthenia Gravis
|
Nov-08 |
$11,400 |
|
|
|
|
Market Watch: Health Round-up
|
Nov-08 |
$400 |
|
|
|
|
Market Watch: Cancer
|
Nov-08 |
$200 |
|
|
|
|
MarketWatch: Biotechnology
|
Nov-08 |
$200 |
|
|
 |
Pipeline Insight: Molecular Targeted Cancer Therapies - More pipeline activity, less product differentiation
|
Nov-08 |
$15,200 |
|
|
 |
Save 30%
Molecular Diagnostics: a primer on an emerging sector
|
Nov-08 |
$5,320 |
|
|
 |
Stakeholder Opinions: Restless Legs Syndrome - Novel drugs to prosper as lifecycle management strategies fail
|
Nov-08 |
$7,600 |
|
|
 |
Pipeline and Commercial Insight: Anxiety Disorders - Viable indication for antipsychotics companies
|
Nov-08 |
$15,200 |
|
|
 |
Stakeholder Insight: Systemic Lupus Erythematosus Imprecise segmentation complicates treatment algorithms
|
Nov-08 |
$15,200 |
|
|
 |
Stakeholder Opinions: Bladder Cancer - New drugs needed to challenge ineffective 20-year old drugs
|
Nov-08 |
$3,800 |
|
|
|
Stakeholder Opinions: Non-hormonal Treatments for Menopausal Symptoms - Market open to takers as tepid pipeline fails to meet demand
|
Jun-08 |
$3,800 |
|
|
|
Pricing & Reimbursement - Seven Major Markets Update
|
May-08 |
$5,700 |
|
|
|
Forecast Insight: Osteoarthritis - The COX-2 pipeline collapses
|
May-08 |
$15,200 |
|
|
|
Pipeline Insight: Acute Stroke: Commercial risk offsets high unmet need
|
May-08 |
$11,400 |
|
|
|
Online patient recruitment and its impact on patient relationship management
|
May-08 |
$3,800 |
|
|
|
PharmaVitae: Company Comparator Tool
|
Jun-08 |
$45,600 |
|
|
|
Drug Repositioning Strategies - Serendipity by design
|
May-08 |
$3,800 |
|
|
|
Stakeholder Opinions: Percutaneous Coronary Intervention - Adverse events with drug-eluting stents demand a new safety standard
|
Apr-08 |
$3,800 |
|
|
|
Stakeholder Opinions: Heart Failure - When drugs do not work
|
Apr-08 |
$3,800 |
|
|
|
|
Pipeline Insight: Nosocomial Vaccines - Minefield or Goldmine?
|
Apr-08 |
$11,400 |
|
|
|
Pipeline Insight: Breast Cancer - Recent approvals increase pressure on pipeline candidates
|
Apr-08 |
$11,400 |
|
|
|
|
Pipeline Insight: Non-Small Cell Lung Cancer - Pipeline set to offer only modest improvements
|
Apr-08 |
$11,400 |
|
|
|
Commercial and Pipeline Insight: HRT for Menopausal Symptoms – A new class restores an old market
|
Apr-08 |
$15,200 |
|
|
|
Commercial and Pipeline Insight: ADHD - Immature adult market continues to offer greatest commercial potential
|
Apr-08 |
$15,200 |
|
|
|
Biotechnology:
Global Industry Guide
|
Oct-07 |
$995 |
|
|
|
Pipeline and Commercial Insight: Influenza Vaccines – Pandemic threat revitalizes the sector
|
Apr-07 |
$15,200 |
|
|
|
|
Pipeline Insight: Depression -
Novel drugs to grow third-line market
|
Mar-07 |
$11,400 |
|
|
|
Stakeholder Opinions: Esophageal Cancer – Treatment paradigms need revolution not evolution
|
Mar-07 |
$11,400 |
|
|
|
Pipeline Insight: Hematological Malignancies – Pursuit for the next blockbuster intensifies
|
Mar-07 |
$11,400 |
|
|
|
Pipeline Insight: Osteoporosis – Intermittent dosing drives market growth
|
Mar-07 |
$11,400 |
|
|
|
The Pharmaceutical Industry: Key trends and strategic issues shaping the
industry
|
14-Feb-07 |
$5700
$5130 |
|
|
|
|
The Pharmaceutical Company Outlook to 2011: Financial and Strategic Analysis of the Sales Outlook for Big Pharma, Mid Pharma, Japan Pharma and Biotech
|
21-Dec-06 |
$7600 |
|
|
|
|
Biosimilars: Benchmarking the key players - With increasing regulatory clarity and high revenue potential, interest in biosimilars increases
|
20-Dec-06 |
$7600 |
|
|
|
|
Commercial Insight: Antibacterials - Growth in resistance rates drives niche indications
|
20-Dec-06 |
$15200 |
|
|
|
|
Stakeholder Insight: Pricing and Reimbursement in Oncology - Do payers believe oncology drugs offer good value?
|
19-Dec-06 |
$11400 |
|
|
|
|
Chinese Pharmaceutical Market Overview - Regulatory reform and the evolving healthcare market provide opportunities in china
|
19-Dec-06 |
$15200 |
|
|
|
|
Biosimilars: Regulatory Issues - Europe continues to make strides while the US lags behind
|
6-Dec-06 |
$3800 |
|
|
|
|
Pipeline/Commercial Insight: Molecular Targeted Cancer Therapies - More drugs on the market, more targets in the pipeline
|
10-Oct-06 |
$15200 |
|
|
|
|
Pharmaceutical Outsourcing Part 2: An Introduction to Drug Discovery Strategies – new opportunities lie in a fully integrated global outsourcing strategy
|
23-Aug-06 |
$3800 |
|
|
|
|
From blockbuster to nichebuster - Niche therapies drive future drugs growth and incentivize R&D investment over sales spending
|
24-Jul-06 |
$1900 |
|
